- Oops!Something went wrong.Please try again later.
EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Personnel
Relief Appoints Dr. Taneli Jouhikainen as Chief Operating Officer
Dr. Taneli Jouhikainen has over 25 years of life sciences expertise. He joins Relief from Savara, a Nasdaq-listed clinical stage biopharmaceutical company focused on rare respiratory diseases, where he was Co-Founder and President & COO. Prior to this, he served at Akela Pharma Inc., a public clinical stage specialty pharmaceutical company focused on orphan drugs and inhalation products, first as Head of Corporate Development and subsequently as CEO until the company's merger with Nventa Biopharmaceuticals. He served in senior executive roles at various other life sciences companies, including LAB International, Inc. and Focus Inhalation Oy, and was Head of Clinical Development at Leiras, a subsidiary of Schering AG. Dr. Jouhikainen holds an M.D. and a Ph.D. in hematology and immunology from the University of Helsinki and an MBA from the Helsinki School of Economics.
"I am intrigued by the opportunity to join Relief at this pivotal time," said Taneli Jouhikainen, M.D., MBA, COO of Relief. "I look forward to contributing my expertise in pharmaceutical business strategy and development as I work closely with the other members of the team not only to advance Relief's exciting current programs but to bring in new products and businesses."
Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief's lead drug candidate RLF-100TM (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. For more information, visit www.relieftherapeutics.com. Follow us on LinkedIn.
Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
End of Media Release
RELIEF THERAPEUTICS Holdings AG
Avenue de Sécheron 15
SIX Swiss Exchange
EQS News ID:
End of News
EQS Group News Service